News
Video
Using Belantamab Mafodotin and Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.
Pharmacy Times® interviewed Suzanne Trudel, MD, MSC, FRCPC, an associate professor at the University of Toronto and a consultant in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto, on one of her presentations at the 62nd ASH Annual Meeting and Exposition. The presentation is on the part 1 results of a dose finding study of belantamab mafodotin (belamaf) in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
In this video, Trudel discusses what belamaf and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.
